APO-DICLOFENAC OPHTHALMIC SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

DICLOFENAC SODIUM

متاح من:

APOTEX INC

ATC رمز:

S01BC03

INN (الاسم الدولي):

DICLOFENAC

جرعة:

0.1%

الشكل الصيدلاني:

SOLUTION

تركيب:

DICLOFENAC SODIUM 0.1%

طريقة التعاطي:

OPHTHALMIC

الوحدات في الحزمة:

2.5/5/10ML FILL

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

NONSTEROIDAL ANTI-INFLAMMATORY AGENTS

ملخص المنتج:

Active ingredient group (AIG) number: 0114417004; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2015-05-12

خصائص المنتج

_APO-DICLOFENAC OPHTHALMIC (Diclofenac Sodium Ophthalmic Solution)_
_Page 1 of 28_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
APO-DICLOFENAC OPHTHALMIC
Diclofenac Sodium Ophthalmic Solution
Ophthalmic solution, 0.1% w/v for Topical use
Anti-inflammatory agents, non-steroids
APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Initial Authorization:
MAY 12, 2015
Date of Revision:
SEP 18, 2023
Submission Control Number: 275184
_APO-DICLOFENAC OPHTHALMIC (Diclofenac Sodium Ophthalmic Solution)_
_Page 2 of 28_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male
Potential
09/2023
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
09/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS ...........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS ...........................................................................................................
4
1.1
Pediatrics
...........................................................................................................
4
1.2
Geriatrics
...........................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
................................................... 4
4.4
Administration
...................................................................................................
5
4.5
Missed Dose
..........................